StockData
Evaxion A/S logo

Evaxion A/S (EVAX) stock

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.78+0.01 (+0.36%)

Close on Nov 17, 2026Market cap $23.19MP/E –Yield –

Evaxion A/S operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Evaxion A/S's operating income for the twelve months ending Jun 30, 2022 was -$26.29M. For fiscal 2025 it was -$9.23M. The highest annual figure on record is -$5.63M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.23M–
FY2024Dec 31, 2024-$14.73M–
FY2023Dec 31, 2023-$22.20M–
FY2022Dec 31, 2022-$25.26M–
FY2021Dec 31, 2021-$25.83M–
FY2020Dec 31, 2020-$16.57M–
FY2019Dec 31, 2019-$10.86M–
FY2018Dec 31, 2018-$5.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.85M–
Q2 FY2025Jun 30, 2025-$4.34M–
Q2 FY2024Jun 30, 2024-$4.58M–
Q2 FY2023Jun 30, 2023-$5.68M–
Q2 FY2022Jun 30, 2022-$6.26M–
Q1 FY2022Mar 31, 2022-$6.40M–
Q4 FY2021Dec 31, 2021-$7.72M–
Q3 FY2021Sep 30, 2021-$5.91M–
Q2 FY2021Jun 30, 2021-$7.03M–
Q1 FY2021Mar 31, 2021-$5.18M–
Q4 FY2020Dec 31, 2020-$4.65M–
Q3 FY2020Sep 30, 2020-$4.69M–
Q2 FY2020Jun 30, 2020-$3.94M–
Q1 FY2020Mar 31, 2020-$3.29M–

More Evaxion A/S figures

See a number that looks wrong?